Exemestane in Hormone Receptor Positive High Grade Ovarian Cancer (EXPERT)
EXemestane in Progesterone and/or Estrogen Receptor Positive Epithelial Ovarian Cancer: A Randomized Phase III Trial, EXPERT
Sponsor: Ente Ospedaliero Ospedali Galliera
Terminated
low accrual, COVID 19 emergency and the modification of the standard of care for ovarian cancer treatment
Other terminated trials from Ente Ospedaliero Ospedali Galliera
See all terminations from Ente Ospedaliero Ospedali Galliera
Listed as NCT04460807, this PHASE3 trial focuses on Ovarian Cancer and remains terminated or withdrawn. Sponsored by Ente Ospedaliero Ospedali Galliera, it has been updated 7 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Mar 2024 — Jul 2024 [monthly]
Terminated PHASE3
Status: Unknown Status → Terminated
-
Mar 2023 — Mar 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jan 2021 — Mar 2023 [monthly]
Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE3
First recorded
Feb 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ente Ospedaliero Ospedali Galliera
- Federation of Italian Cooperative Oncology Groups
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Istituto Di Ricerche Farmacologiche Mario Negri
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Alba, Italy , Alessandria, Italy , Aviano, Italy , Bari, Italy , Biella, Italy , Bologna, Italy , Brescia, Italy , Cagliari, Italy , Candiolo, Italy , Catania, Italy and 31 more locations